Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 242-247

  Choi, Hongyoon ^a   Paeng, Jin Chul ^a   Kim, Dong Wan ^a,b   Lee, June Koo ^a   Park, Chang Min ^a,b   Kang, Keon Wook ^a,b   Chung, June Key ^a,b   Lee, Dong Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

ALK rearrangement; EGFR mutation; FDG PET CT; Lung cancer; Metabolism; SUV

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; FLUORODEOXYGLUCOSE F18; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84873106556     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.11.021     Document Type: Article

References (40)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Ramalingam S.S., Owonikoko T.K., Khuri F.R. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011, 61:91-112.
3. Ladanyi M., Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008, 21(Suppl. 2):S16-S22.
4. Kerr K.M. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009, 54:12-27.
5. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
6. Naoki K., Chen T.H., Richards W.G., Sugarbaker D.J., Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002, 62:7001-7003.
7. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62:6997-7000.
8. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359:1367-1380.
9. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
10. Herbst R.S., Lippman S.M. Molecular signatures of lung cancer-toward personalized therapy. N Engl J Med 2007, 356:76-78.
11. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
12. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
13. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
14. Inamura K., Takeuchi K., Togashi Y., Nomura K., Ninomiya H., Okui M., et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008, 3:13-17.
15. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
16. Vesselle H., Schmidt R.A., Pugsley J.M., Li M., Kohlmyer S.G., Vallires E., et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000, 6:3837-3844.
17. Higashi K., Ueda Y., Sakurai A., Wang X.M., Xu L., Murakami M., et al. Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med 2000, 27:1778-1785.
18. Ito T., Noguchi Y., Satoh S., Hayashi H., Inayama Y., Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998, 11:437-443.
19. Nguyen X.C., Lee W.W., Chung J.H., Park S.Y., Sung S.W., Kim Y.K., et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 2007, 62:214-219.
20. Jadvar H., Alavi A., Gambhir S.S. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 2009, 50:1820-1827.
21. Huang C.T., Yen R.F., Cheng M.F., Hsu Y.C., Wei P.F., Tsai Y.J., et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Med Oncol 2010, 27:9-15.
22. Na I.I., Byun B.H., Kim K.M., Cheon G.J., Choe du H., Koh J.S., et al. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer 2010, 67:76-80.
23. Mak R.H., Digumarthy S.R., Muzikansky A., Engelman J.A., Shepard J.A., Choi N.C., et al. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 2011, 16:319-326.
24. Wong D.W., Leung E.L., So K.K., Tam I.Y., Sihoe A.D., Cheng L.C., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115:1723-1733.
25. Paik J.H., Choi C.M., Kim H., Jang S.J., Choe G., Kim D.K., et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012, 76:403-409.
26. Takahashi T., Sonobe M., Kobayashi M., Yoshizawa A., Menju T., Nakayama E., et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010, 17:889-897.
27. Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-5223.
28. Edge S.B. American Joint Committee on Cancer. AJCC cancer staging manual 2010, Springer, New York. 7th ed.
29. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-4283.
30. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
31. Doebele R.C., Lu X., Sumey C., Maxson D.A., Weickhardt A.J., Oton A.B., et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012, 118:4502-4511.
32. Lee J.K., Park H.S., Kim D.W., Kulig K., Kim T.M., Lee S.H., et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer 2012, 118:3579-3586.
33. Yang P., Kulig K., Boland J.M., Erickson-Johnson M.R., Oliveira A.M., Wampfler J., et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012, 7:90-97.
34. Berghmans T., Dusart M., Paesmans M., Hossein-Foucher C., Buvat I., Castaigne C., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008, 3:6-12.
35. Nair V.S., Krupitskaya Y., Gould M.K. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol 2009, 4:1473-1479.
36. Fukui T., Yatabe Y., Kobayashi Y., Tomizawa K., Ito S., Hatooka S., et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 2012, 77:319-325.
37. Park E.A., Lee H.J., Kim Y.T., Kang C.H., Kang K.W., Jeon Y.K., et al. EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT,FDG-PET, and histopathology. Lung Cancer 2009, 64:179-186.
38. Okada M., Tauchi S., Iwanaga K., Mimura T., Kitamura Y., Watanabe H., et al. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas. J Thorac Cardiovasc Surg 2007, 133:1448-1454.
39. Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-5223.
40. Wang Y.W., Tu P.H., Lin K.T., Lin S.C., Ko J.Y., Jou Y.S. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer. Neoplasia 2011, 13:704-715.